Categories
Prostate cancer

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

  • Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–6249s.

    PubMed 
    Article 

    Google Scholar
     

  • Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–7.

    PubMed 
    Article 

    Google Scholar
     

  • Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42–50.

    PubMed 
    Article 

    Google Scholar
     

  • Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16:579–84.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16:571–5.

    PubMed 
    Article 

    Google Scholar
     

  • Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2017;35:664.e661–664.e669.

    Article 

    Google Scholar
     

  • Chipperfield K, Fletcher J, Millar J, Brooker J, Smith R, Frydenberg M, et al. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psychooncology. 2013;22:2169–76.

    PubMed 
    Article 

    Google Scholar
     

  • Guan T, Santacroce SJ, Chen DG, Song L. Illness uncertainty, coping, and quality of life among patients with prostate cancer. Psychooncology. 2020;29:1019–25.

    PubMed 
    Article 

    Google Scholar
     

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Parker C, Finkelstein SE, Michalski JM, O’Sullivan JM, Bruland O, Vogelzang NJ, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70:875–83.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27:868–74.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Badrising SK, Louhanepessy RD, van der Noort V, Kieffer J, Coenen J, Hamberg P, et al. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. Prostate Cancer Prostatic Dis. 2022;25:248–55.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Parimi S, Bondy S, Tsang E, McKenzie MR, Bachand F, Aparicio M, et al. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer. Can Urol Assoc J. 2019;13:E311–E316.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Morris MJ, Sartor O, Vogelzang NJ, Shore ND, Cislo P, Bangerter K, et al. Effect of radium-223 dichloride (Ra-223) on pain from US EAP. J Clin Oncol. 2015;33:160–160.

    Article 

    Google Scholar
     

  • Kuppen MCP, Westgeest HM, van den Eertwegh AJM, Coenen J, van Moorselaar RJA, van den Berg P, et al. Health-related quality of life and pain in a real-world castration-resistant prostate cancer population: results from the PRO-CAPRI study in the Netherlands. Clin Genitourin Cancer. 2020;18:e233–e253.

    PubMed 
    Article 

    Google Scholar
     

  • Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19:111–21.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, et al. Health-related quality of life in patients with advanced prostate cancer: a systematic review. Eur Urol Focus. 2021;7:742–51.

    PubMed 
    Article 

    Google Scholar
     

  • Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, et al. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer. 2009;45:1146–52.

    PubMed 
    Article 

    Google Scholar
     

  • Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, et al. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer. 2012;118:1457–65.

    PubMed 
    Article 

    Google Scholar
     

  • Scott NW, Fayers P, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 reference values manual. EORTC Quality of Life Group, Brussels, Belgium 2008.

  • Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res. 2006;12:6236s–6242s.

    PubMed 
    Article 

    Google Scholar
     

  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6:46.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383–92.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P, et al. The assessment of fatigue: psychometric qualities and norms for the Checklist individual strength. J Psychosom Res. 2017;98:40–46.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79–88.

    PubMed 
    Article 

    Google Scholar
     

  • Husson O, de Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK, et al. The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “Real-World”: results from the population-based PROFILES registry. Oncologist. 2020;25:e722–e732.

    PubMed 
    Article 

    Google Scholar
     

  • Westdorp H, Creemers JHA, van Oort IM, Mehra N, Hins-de Bree SM, Figdor CG. et al. High health-related quality of life during dendritic cell vaccination therapy in patients with castration-resistant prostate cancer. Front Oncol. 2020;10:536700

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Sraieb M, Hirmas N, Conrad R, Marinova M, Essler M, Herrmann K, et al. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy. Medicines. 2020;99:e22287.

    CAS 

    Google Scholar
     

  • Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2006;15:1297–306.

    PubMed 
    Article 

    Google Scholar
     

  • Frantellizzi V, De Feo MS, Di Rocco A, Pontico M, Pani A, Farcomeni A, et al. Baseline quality of life predicts overall survival in patients with mCRPC treated with (223)Ra-dichloride. Hell J Nucl Med. 2020;23:12–20.

    PubMed 

    Google Scholar
     

  • De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R, et al. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. Eur J Cancer Care. 2019;28:e13112.

    Article 

    Google Scholar
     

  • van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives. Clin Genitourin Cancer. 2019;17:79–87.

    PubMed 
    Article 

    Google Scholar
     

  • van der Doelen MJ, Stockhaus A, Ma Y, Mehra N, Yachnin J, Gerritsen WR, et al. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. Eur J Nucl Med Mol Imaging. 2021;48:3325–34.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Wintner LM, Sztankay M, Aaronson N, Bottomley A, Giesinger JM, Groenvold M, et al. The use of EORTC measures in daily clinical practice—a synopsis of a newly developed manual. Eur J Cancer. 2016;68:73–81.

    PubMed 
    Article 

    Google Scholar
     

  • Leave a Reply